Paul Tudor Jones Theravance Biopharma, Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 177,612 shares of TBPH stock, worth $1.51 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

177,612

Previous 10,083 1661.5%

Holding current value

$1.51 Million

Previous $113,000 1309.73%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.22 - $11.59 $1.38 Million - $1.94 Million	167,529 Added 1661.5%	177,612 $1.59 Million
Q4 2023 Feb 14, 2024	SELL	$8.58 - $11.4 $837,965 - $1.11 Million	-97,665 Reduced 90.64%	10,083 $113,000
Q3 2023 Nov 15, 2023	SELL	$8.38 - $10.44 $116,632 - $145,303	-13,918 Reduced 11.44%	107,748 $929,000
Q2 2023 Aug 14, 2023	BUY	$10.16 - $11.92 $132,394 - $155,329	13,031 Added 12.0%	121,666 $1.26 Million
Q1 2023 May 15, 2023	BUY	$9.87 - $11.44 $150,033 - $173,899	15,201 Added 16.27%	108,635 $1.18 Million

Q4 2022 Feb 14, 2023	BUY	$9.65 - $11.34 $901,638 - $1.06 Million	93,434 New	93,434 $1.05 Million
Q2 2022 Aug 15, 2022	BUY	$8.41 - $10.34 $600,171 - $737,903	71,364 Added 223.6%	103,280 $936,000
Q1 2022 May 16, 2022	SELL	$8.33 - $12.96 $1.18 Million - $1.83 Million	-141,498 Reduced 81.6%	31,916 $305,000
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $903,051 - $1.34 Million	121,705 Added 235.37%	173,414 $1.92 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $350,069 - $745,126	51,709 New	51,709 $383,000

Others Institutions Holding TBPH

# of Institutions

124

Shares Held

49.6M

Call Options Held

1.4K

Put Options Held

2.3K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $566M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account